Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DOC 1021

Next Previous
Search
Drug Profile

DOC 1021

Alternative Names: Dendritic cell cancer vaccine - Diakonos Oncology; DOC-1021

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diakonos Research
  • Developer Baylor College of Medicine; Diakonos Oncology
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adenocarcinoma; Glioblastoma; Sarcoma
  • Discontinued Prostate cancer; Triple negative breast cancer

Most Recent Events

  • 03 Feb 2025 Diakonos Oncology Corporation plans a phase II trial for Glioblastoma (Combination-therapy, First-line therapy) in March 2025 (SC, Injection) (NCT06805305)
  • 10 Jan 2025 Diakonos Oncology plans clinical trial for Malignant melanoma (Metastatic disease, Second-line therapy or greater) in 2025 (Parenteral)
  • 01 Oct 2024 Adverse events and efficacy data from a phase I trial in Glioblastoma released by Diakonos Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top